Sanjivani Paranteral Q1 FY27: PAT up 33% on standalone, 44% consolidated

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹188.00

prior close

₹192.70

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+4.2% vs market

Pharmaceuticals peers, median of 166sector-0.4%+4.7% vs sector

On the reaction day the stock moved 4.2 pts more than Nifty Microcap 250 and 4.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.5

10m

-0.3

15m

+1.2

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3+0.1+4.2-0.4+4.7

Next day

+2.6+0.2+2.4-0.5+3.0

+6.4+0.6+5.8-0.6+6.9

+4.3-0.0+4.3-1.4+5.7

+1.1+0.5+0.6-0.9+2.0

+1.6+0.8+0.9-0.4+2.0

-0.4+0.6-1.0-0.9+0.5

15d

+1.1+1.3-0.2+0.0+1.1

-4.5-1.4-3.1-0.1-4.4

-6.6-0.6-6.1-2.6-4.0

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone revenue from operations rose 8.7% YoY to Rs 1945.84 lacs (vs Rs 1789.22 lacs in Q1 FY26). Net profit grew 32.6% to Rs 229.54 lacs from Rs 173.06 lacs. PBT stood at Rs 306.05 lacs. EPS at Rs 1.87 vs Rs 1.46. On consolidated basis, revenue grew 33% to Rs 2383.92 lacs and PAT rose 44% to Rs 249.11 lacs, helped by subsidiary SPL Infusion. Operating margins expanded. Auditors R.B. Gohil and Co issued an unmodified opinion. AGM scheduled for 16 September 2026.

Likely market impact

Strong profit growth on both standalone and consolidated basis signals healthy business momentum, supportive for shareholders.